Head to head
Cagrilintide against Pramlintide
The investigational amylin analogue and the only amylin analogue ever approved. The approved one is a different story than it sounds: Drugs@FDA lists every Symlin product as discontinued, so the class has an approval history and no marketed product.
Column A
CagrilintideCagrilintide (long-acting amylin receptor agonist)
An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Column B
PramlintidePramlintide (amylin analogue)
The only amylin analogue ever approved for diabetes, and the FDA now lists every Symlin product as discontinued. Approved is not the same as available.
Side by side, on the facts we can check
| Attribute | Cagrilintide | Pramlintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved | Approved as Symlin, but Drugs@FDA lists every Symlin product as Discontinued as of September 2026. Approved and marketed are different things and this is the gap between them. |
| Half-life | ~7 days | ~48 minutes |
| Molecular weight | ~3,700 Da | 3,949.4 Da |
| Mechanism | Agonizes amylin receptors in the hypothalamus and brainstem to promote satiety and delay gastric emptying, complementing GLP-1 signaling. | Agonizes amylin receptors to delay gastric emptying, suppress post-meal glucagon, and promote satiety, complementing insulin. |
| Human studies cited | 3 | 4 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Cagrilintide and Pramlintide?
Cagrilintide: An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss. Pramlintide: The only amylin analogue ever approved for diabetes, and the FDA now lists every Symlin product as discontinued. Approved is not the same as available.
Which has stronger research evidence, Cagrilintide or Pramlintide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Cagrilintide profile were human work, against 4 of 4 for Pramlintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Cagrilintide and Pramlintide FDA-approved?
Cagrilintide: Investigational, not FDA-approved. Pramlintide: Approved as Symlin, but Drugs@FDA lists every Symlin product as Discontinued as of September 2026. Approved and marketed are different things and this is the gap between them..
Related posts
Blog articles that cover Cagrilintide or Pramlintide, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.